Roche Holding AG, founded in 1896 in Basel, Switzerland, has evolved from a small pharmaceutical company into a global leader in healthcare, pioneering innovative drugs and diagnostics. With key milestones including the development of benzodiazepines, blockbuster cancer therapies, and strategic acquisitions of Genentech and Spark Therapeutics, Roche has consistently shaped modern medicine and maintained a strong presence on the SIX Swiss Exchange.
Fritz Hoffmann-La Roche establishes Hoffmann-La Roche & Co. in Basel, Switzerland, focusing on the production of pharmaceutical preparations. #history #business
Roche begins manufacturing its first pharmaceutical products, including tonics and digestive preparations, laying the foundation for its future drug development. #pharma #history
Roche establishes its first foreign subsidiary in Grenzach, Germany, marking the beginning of its international expansion. #expansion #business
Roche introduces Pantopon, a highly purified opium alkaloid mixture, as a painkiller and sedative. #pharma #innovation
Roche issued its first public shares on the Basel stock exchange (now SIX Swiss Exchange), providing capital for further growth. #finance #ipo
Roche introduces Allonal, a barbiturate-based sedative-hypnotic drug, which becomes widely used. #pharma #drugs
Roche scientists develop the first industrial synthesis of vitamin C, launching Redoxon, a landmark in nutritional science. #science #vitamins
Roche contributes to the discovery and development of sulfonamide antibiotics, revolutionizing infection treatment. #medicine #antibiotics
Roche begins large-scale production of penicillin for Allied forces, expanding its manufacturing capabilities. #wartime #pharma
Roche launches Rimactane, a powerful antibiotic used against tuberculosis, later combined with isoniazid. #tb #antibiotics
Roche introduces Librium (chlordiazepoxide), the first benzodiazepine, ushering in a new class of anxiolytic drugs. #mentalhealth #drugs
Roche launches Valium, which becomes one of the most prescribed drugs globally for anxiety and muscle relaxation. #pharma #blockbuster
Roche enters the diagnostics market, beginning a division that would become a major pillar of the company. #diagnostics #expansion
Roche acquires a diagnostics firm, strengthening its position in in vitro diagnostics. #acquisition
Roche introduces Roaccutane for severe acne, a breakthrough treatment that transforms dermatology. #dermatology #drugs
Roche launches Hivid, one of the first antiretroviral drugs for HIV/AIDS, though later withdrawn due to side effects. #hiv #aids
Roche purchases a 60% majority stake in Genentech, gaining access to cutting-edge biotechnology. #biotech #acquisition
Roche acquires Syntex, adding Naprosyn (naproxen) and other anti-inflammatory drugs to its portfolio. #pharma #acquisition
Roche acquires the diagnostics division of Boehringer Mannheim, becoming a world leader in in vitro diagnostics. #diagnostics #acquisition
Roche launches Herceptin, a targeted therapy for HER2-positive breast cancer, a milestone in personalized medicine. #cancer #biotech
Roche launches Tamiflu, an antiviral drug for influenza, developed in partnership with Gilead Sciences. #flu #antiviral
Roche launches rituximab, a monoclonal antibody for non-Hodgkin lymphoma and autoimmune diseases. #cancer #immunotherapy
Roche introduces Pegasys for hepatitis C, a pegylated interferon that improves treatment outcomes. #hepatitis #antiviral
Roche launches Avastin, an anti-angiogenic cancer drug that becomes a blockbuster for multiple tumor types. #cancer #biotech
Roche launches Tarceva, a targeted therapy for non-small cell lung cancer and pancreatic cancer. #cancer #targetedtherapy
Roche acquires Ventana, a leader in tissue-based diagnostics, for $3.4 billion. #diagnostics #acquisition
Roche acquires the remaining 40% of Genentech for approximately $47 billion, making it a wholly owned subsidiary. #biotech #acquisition
Roche launches Lucentis for wet age-related macular degeneration, a leading cause of blindness. #ophthalmology #drugs
Roche launches Perjeta, a HER2 dimerization inhibitor for breast cancer, often used with Herceptin. #cancer #biotech
Roche launches Kadcyla, an antibody-drug conjugate for HER2-positive breast cancer. #cancer #antibodydrugconjugate
Roche acquires Seragon Pharmaceuticals, gaining access to novel oncology therapies. #oncology #acquisition
Roche launches Ocrevus, the first drug approved for both relapsing and primary progressive multiple sclerosis. #multiplesclerosis #neurology
Roche acquires Flatiron Health, a health technology company specializing in oncology data analytics, for $1.9 billion. #healthtech #data
Roche acquires Spark Therapeutics, a gene therapy pioneer, for $4.8 billion, entering the gene therapy field. #genetherapy #acquisition
Roche rapidly develops and commercializes multiple COVID-19 diagnostic tests, contributing to pandemic response. #covid19 #diagnostics
Roche launches Evrysdi, an oral therapy for spinal muscular atrophy (SMA), offering a new treatment option. #neurology #raredisease
Roche acquires Good Therapeutics, a developer of PD-1-regulated IL-2 therapies for cancer, in a $250 million deal. #oncology #acquisition
Roche launches Vabysmo for diabetic macular edema and wet AMD, a bispecific antibody with longer dosing intervals. #ophthalmology #biotech
